Subtype
Male Reproductive System Neoplasm
CI-CAN-00001107Explore in graph →
Non-malignant1,533 active trials27 approved drugs58 evidence items
- NCIt
- C3054
Loading cancer entity…
Subtype
CI-CAN-00001107Explore in graph →
Clinical trials
6,899 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03361735 | Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer | active not recruiting | Phase 2 | 25 | City of Hope Medical CenterOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT00859781 | 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer | active not recruiting | Phase 2 | 55 | Weill Medical College of Cornell UniversityOTHER | 1 | Apr 8, 2026 |
| clinicaltrials |
| NCT03361436 | Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by Surgery | active not recruiting | Phase 1 | 15 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT03827616 | Moderately Hypofractionated Radiotherapy for Prostate Cancer. | active not recruiting | N/A | 400 | Tatarstan Cancer CenterOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT06303713 | LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer | active not recruiting | Phase 1 | 37 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT06402331 | FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)(AlphaBreak) | active not recruiting | Phase 2 | 110 | Fusion Pharmaceuticals Inc.INDUSTRY | 1 | Apr 8, 2026 | clinicaltrials |
| NCT00579514 | Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients | active not recruiting | N/A | 21,081 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT07214961 | Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)(ARTISAN) | active not recruiting | Phase 1 | 80 | ARTBIO Inc.INDUSTRY | 1 | Apr 7, 2026 | clinicaltrials |
| NCT04709276 | A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer(CHAMP) | active not recruiting | Phase 2 | 41 | Andrew J. Armstrong, MDOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT04147806 | A Pilot Study of Ultra-High-Dose Hypofractionated or Single-Dose Radiotherapy for Intermediate Risk Prostate Cancer(PROSINT) | active not recruiting | Phase 1 | 31 | Albert Einstein College of MedicineOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT05219500 | Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).(TATCIST) | active not recruiting | Phase 2 | 115 | Fusion Pharmaceuticals Inc.INDUSTRY | 1 | Apr 3, 2026 | clinicaltrials |
| NCT04300855 | Clinical Trial of Green Tea Catechins in Men on Active Surveillance | active not recruiting | Phase 2 | 115 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT04357925 | Quality of Life in Prostate Cancer Patients(QoLProstateMQ) | active not recruiting | — | 304 | University Hospital Center of MartiniqueOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT05266313 | Contributions of a Paramedical Approach in the Prevention and Treatment of Side Effects Associated With Radical Prostatectomy(VITALITE) | active not recruiting | N/A | 135 | University Hospital Center of MartiniqueOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT03471650 | Study of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate Cancer | active not recruiting | Phase 2 | 150 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT03860272 | Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer | active not recruiting | Phase 1 | 499 | Agenus Inc.INDUSTRY | 2 | Mar 30, 2026 | clinicaltrials |
| NCT04663997 | 177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer | active not recruiting | Phase 2 | 200 | Canadian Cancer Trials GroupNETWORK | 1 | Mar 27, 2026 | clinicaltrials |
| NCT05678322 | Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical Prostatectomy | active not recruiting | Phase 3 | 26 | NYU Langone HealthOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT01441687 | Comparing the Reliability of Expressed Prostatic Secretion (EPS) and Post Massage Urine (PMU) for the Prediction of Prostate Cancer Biopsy Outcome | active not recruiting | N/A | 243 | City of Hope Medical CenterOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT02722525 | Cardiac MRI in Measuring the Impact of Anti-androgen Treatment on Cardiac Function in Patients With Prostate Cancer | active not recruiting | N/A | 23 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT03787680 | Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial) | active not recruiting | Phase 2 | 49 | University of Michigan Rogel Cancer CenterOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT05096338 | Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Prostate Cancer(PCT) | active not recruiting | — | 200 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT05658003 | A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer | active not recruiting | Phase 2 | 63 | Novartis PharmaceuticalsINDUSTRY | 1 | Mar 23, 2026 | clinicaltrials |
| NCT06018311 | Hispanic Adapted and Culturally Relevant Exercising Together(HACER) | active not recruiting | N/A | 58 | University of ArizonaOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT06126172 | Radiomics of Treatment-naive Prostate Cancer Patients on Multiparametric MRI for Risk Stratification and Treatment Outcomes Predictions | active not recruiting | N/A | 125 | Chang Gung Memorial HospitalOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT03412396 | Apalutamide in Treating Patients With Prostate Cancer Before Radical Prostatectomy | active not recruiting | Phase 2 | 45 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT04262609 | Faecal Incontinence in Prostate Cancer Survivors Treated Whith Radiotherapy | active not recruiting | — | 200 | Consorci Sanitari de TerrassaOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT03663218 | PRE-ProstAtectomy MRI-GuidEd Stereotactic Body RadioTherapy for High-Risk Prostate Cancer Trial (PREPARE SBRT)(PREPARE SBRT) | active not recruiting | N/A | 16 | Weill Medical College of Cornell UniversityOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT05343936 | Evaluation of an Active Surveillance Protocol for Prostate Cancer in the Brazilian Population | active not recruiting | — | 490 | Hospital Moinhos de VentoOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT06307704 | Lung US for PEEP Optimization in Robotic Radical Prostatectomy or Cystectomy Patients | active not recruiting | N/A | 88 | Nazmy Edward SeifOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT06408597 | Mannitol Versus Nitroglycerin for Kidney Injury Prevention in Robotic-assisted Radical Prostatectomy or Cystectomy | active not recruiting | N/A | 90 | Nazmy Edward SeifOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT05245006 | PET Imaging Study of 89Zr-DFO-YS5 in Men With Prostate Cancer | active not recruiting | Phase 1 | 30 | Robert Flavell, MD, PhDOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT04435756 | A Study of miRNA 371 in Patients With Germ Cell Tumors | active not recruiting | — | 956 | SWOG Cancer Research NetworkNETWORK | 3 | Mar 12, 2026 | clinicaltrials |
| NCT04845503 | Stereotactic MRI-guided Radiation Therapy for Localized prostatE Cancer(SMILE) | active not recruiting | N/A | 68 | University Hospital HeidelbergOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT00578240 | Molecular Studies and Clinical Correlations in Human Prostatic Disease | active not recruiting | — | 5,290 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT02905318 | Palbociclib in Patients With Metastatic Castration-Resistant Prostate Cancer | active not recruiting | Phase 2 | 19 | Canadian Cancer Trials GroupNETWORK | 1 | Mar 9, 2026 | clinicaltrials |
| NCT03561220 | A Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate Cancer(COMPPARE) | active not recruiting | N/A | 3,000 | University of FloridaOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT03778112 | MRI Guided SBRT for Localized Prostate Cancer | active not recruiting | N/A | 54 | Rush University Medical CenterOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT03808077 | The Effect of Deep Versus Moderate Muscle Relaxants in Men During and After Robotic Surgery for Prostate Cancer | active not recruiting | Phase 2 | 139 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT06463457 | Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED) | active not recruiting | Phase 2 | 33 | Atish Choudhury, MDOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT05331638 | Prostate Cancer Genius App Education and Home-based PSA Screening for African American Men(PCGA) | active not recruiting | N/A | 80 | University of OklahomaOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT05364229 | MR-guided Tumour Boost(MRL-Boost PC) | active not recruiting | N/A | 40 | University Health Network, TorontoOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT03938649 | SRAM study_Postate Cancer | active not recruiting | Phase 2 | 120 | CCTUOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT05154162 | PSMA PET Additive Value for Prostate Cancer Diagnosis in Men With Negative/Equivocal MRI(PRIMARY2) | active not recruiting | Phase 3 | 660 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT05546268 | Study of Oral MRT-2359 in Selected Cancer Patients | active not recruiting | Phase 1 / Phase 2 | 174 | Monte Rosa Therapeutics, IncINDUSTRY | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07431684 | Sense of Coherence and Quality of Life in Prostate Cancer Patients Treated With Radical Radiotherapy | active not recruiting | N/A | 250 | Institute of Oncology LjubljanaOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT02723734 | Validation Study on the Impact of Decipher® Testing - VANDAAM Study(VANDAAM) | active not recruiting | — | 240 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT04422132 | Randomized Phase II Trial of Salvage Radiotherapy for Prostate Cancer In 4 Weeks v. 2 Weeks | active not recruiting | Phase 2 | 134 | Weill Medical College of Cornell UniversityOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04943536 | Bicalutamide Implants (Biolen) With Radiation Therapy in Patients With Localized Prostate Cancer(BiolenRT) | active not recruiting | Phase 1 | 20 | Alessa Therapeutics Inc.INDUSTRY | 1 | Feb 27, 2026 | clinicaltrials |
| NCT02296229 | Stereotactic Body Radiation Therapy in Treating Patients With Localized High-Risk Prostate Cancer | active not recruiting | N/A | 220 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 25, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 9, 2026source: clinicaltrials